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Abstract
Background: It is well known that estrogen receptor α (ERα) participates in the pathogenic progress of breast
cancer, hepatocellular carcinoma and head and neck squamous cell carcinoma. In neuroblastoma cells and related
cancer clinical specimens, moreover, the ectopic expression of ERα has been identified. However, the detailed
function of ERα in the proliferation of neuroblastoma cell is yet unclear.
Methods: The transcriptional activity of ETS-1 (E26 transformation specific sequence 1) was measured by luciferase
analysis. Western blot assays and Real-time RT-PCR were used to examine the expression of ERα, ETS-1 and its targeted
genes. The protein-protein interaction between ERα and ETS-1 was determined by co-IP and GST-Pull down assays. The
accumulation of ETS-1 in nuclear was detected by western blot assays, and the recruitment of ETS-1 to its targeted
gene’s promoter was tested by ChIP assays. Moreover, SH-SY5Y cells’ proliferation, anchor-independent growth,
migration and invasion were quantified using the MTT, soft agar or Trans-well assay, respectively.
Results: The transcriptional activity of ETS-1 was significantly increased following estrogen treatment, and this effect was
related to ligand-mediated activation of ERα. The interaction between the ERα and ETS-1 was identified, and enhancement
of ERα activation would up-regulate the ETS-1 transcription factor activity via modulating its cytoplasm/nucleus
translocation and the recruitment of ETS-1 to its target gene’s promoter. Furthermore, treatment of estrogen increased
proliferation, migration and invasion of neuroblastoma cells, whereas the antagonist of ERα reduced those effects.
Conclusions: In this study, we provided evidences that activation of ERα promoted neuroblastoma cells proliferation and
up-regulated the transcriptional activity of ETS-1. By investigating the role of ERα in the ETS-1 activity regulation, we
demonstrated that ERα may be a novel ETS-1 co-activator and thus a potential therapeutic target in human neuroblastoma
treatment.
Background
Estrogen is one of the key regulators of the development
and progression of several cancers, such as breast cancer
[1–6]. In mammalian cells, estrogen is recognized by estro-
gen receptors (ERs) [1]. Among these nuclear receptors,
ERα contains a ligand-independent activation function do-
main 1 (AF-1 domain) in N-terminal and an AF-2 domain
in C-terminal, and a DNA binding domain (DBD domain)
in between [2]. In cell nucleus, ERα modulates the expres-
sion of estrogen response genes via binding to ERE (estro-
gen responsive element) sequence on their promoter [1–3].
The cross-talk between ERα and EGFR (Epidermal growth
factor receptor) pathway has been reported in lung can-
cer, esophagus cancer and neck squamous cell carcin-
oma [4]. Recently, expression of ERα has been identified
in neuroblastoma cells [5]. Several studies showed that
ERα crosstalks with IGF-IR in regulating proliferation of
neuroprotection and neuroblastoma [6]. However, the
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detailed function of ERα in the proliferation, migration or
invasion of neuroblastoma cells has not been uncovered.
The transcription factor ETS-1 (E26 transformation
specific sequence 1) belongs to ETS protein family [7]. It
contains an ETS domain (transcription activation do-
main) and a helix DNA-binding domain [7]. ETS family
is involved in the regulation of cancer cells’ proliferation,
development, apoptosis, metastasis, invasion and angio-
genesis [7]. High level of ETS-1 was identified in breast
cancer, ovarian cancer and cervical carcinoma [8]. In nu-
cleus, ETS-1 regulates expression of several target genes,
such as MMP1, MMP9, u-PA and c-Met, via binding to
ETS-binding site (EBS, the 5′-GGAA/T-3′ sequence
motif ) within the promoter regions of those genes in
presence of hepatocyte growth factor (HGF) [8]. Some
co-regulators participate in ETS-1 activity, such as SRC-
1 (steroid receptor coactivator 1), AIB-1 (amplified in
breast cancer1) and NCoR [8, 9]. Myers et al., 2009 and
Kalet et al., 2013 provided the evidences that ETS-1
would modulate the activity of ERα and promoted the
proliferation of breast cancer via ERα response genes
[8, 9]. It is valuable to declare the interaction between
ETS-1 and ERα.
Several evidences also demonstrated that transcription
factors or nuclear receptors could crosstalk in a feedback
way [10–12]. For example, aryl hydrocarbon receptor
(AHR) can up-regulate ER signaling through protein-
interaction [10]; whereas ER can also repress AHR target
genes’ transcription [11]. Given that ERα could enhance
the expression of MMPs [12], we therefore decided to
examine whether ERα could modulate ETS-1’s activity
in neuroblastoma, an ERα positive human cancer. In this
study, we found that ERα interacts with ETS-1 in neuro-
blastoma cell. Transcriptional activity of ETS-1 was
significantly increased when ERα had been activated by
estrogen. Estrogen mediated ERα activation significantly
promoted the proliferation, migration and invasion of
neuroblastoma Cell. Our results suggested that ERα
would enhance ETS-1’s activity via promoting its cyto-
plasm/nucleus translocation, recruiting ETS-1 to the




The sequences of ETS-1 or ERα with or without FLAG
sequence was generated by PCR amplification from vec-
tors contain full length sequences (Origene Company,
USA) and cloned into pcDNA3.1 plasmids. Luciferase
reporter genes, mmp1, mmp9, c-Met and uPA [13], EBS
(GGAT) 8 sequences were synthesized by using chemical
synthesis methods (Gene Ray Company, Shanghai,
China) and were cloned into pGL4.26 plasmid. The ex-
pression vectors of SRC-1 and AIB-1 were also obtained
from Origene Company, USA. The siRNA targeted to
ERα or ETS-1 was obtained from Santa Cruz Biotech
Company, USA. The expression vectors of NCoR and
SMRT were gift from Dr. Jiajun Cui [14]. All vectors
were confirmed by DNA sequencing.
Cell culture and reagents
ARQ-197 (c-Met inhibitor) was descripted in reference
[15]. E2 (the agonist of ERα, 17-β-estradiol) and ICI-
182780 (the antagonist of ERα) were from Sigma (St. Louis,
MO, USA), and other agents (Amersham Biosciences,
Piscataway, NJ, USA) were used. Agents were configured to
10 mM DMSO solution, stored in 4 °C. Recombinant hu-
man HGF was obtained from Pepro-Tech (Rocky Hill, NJ,
USA). Human neuroblastoma cell line SH-SY5Y (ERα posi-
tive) and breast cancer cell line MDA-MB-231 (ERα nega-
tive), were from cell resources center of Chinese Academy
of Medical Sciences & Peking Union Medical College in
China. Cells were cultured in complete Dulbecco’s modi-
fied Eagle’s medium (DMEM) (Invitrogen, Carlsbad, CA)
in a sterile incubator maintained at 37 °C with 5 % CO2.
HEK293 cells were obtained from American Type Culture
Collection (ATCC), and were cultured in Roswell Park
Memorial Institute 1640 (RPMI1640) medium (Invitrogen,
Carlsbad, CA) in a sterile incubator maintained at 37 °C
with 5 % CO2.
Stable transfection
SH-SY5Y cells were transfected with empty vector, ETS-1
vector, ERα vector, control siRNA, ETS-1 siRNA or ERα
siRNA; and MDA-MB-231 cells were transfected with
empty vector or ERα vector by using Lipofectamine 2000
(Invitrogen, Carlsbad, CA). Then, transfected cells were
cultured in 200–500 μg/ml G418 (Invitrogen, Carlsbad,
CA) for approximately 2 months. Individual clones were
screened by Western Blotting analysis using anti-ETS1 or
anti-ERα antibody. Similar results were observed with
stable transfection or transient transfection, the individual
clones or pool clones.
Luciferase assay
SH-SY5Y and MDA-MB-231 cells were seeded in 24-well
plates (Corning, NY, USA) in phenol red-free DMEM
(Gibco, Grand Island, NY, USA) supplemented with 0.5 %
charcoal-stripped FBS (Hyclone, Logan, UT, USA).
Transfection was performed using Lipofectamine 2000
(Invitrogen, Carlsbad, CA). Cells were co-transfected with
luciferase reporters and then harvested for analysis of lu-
ciferase and β-galactosidase activities following protocols
descripted in reference [16]. The luciferase assays were
performed without or with indicated concentration of E2,
ICI-182780, ARQ-197 or HGF. Similar results were ob-
tained from three independent experiments.
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RNA isolation and real-time RT-PCR
Total RNA was extracted using the PARISTM Kit (Applied
Biosystems, Foster City, CA) according to the manufac-
turer’s instructions. Multiscribe TM Reverse Transcriptase
(Applied Biosystems, Foster City, CA) was used to
synthesize the complementary DNA templates. Real-time
reverse transcription–polymerase chain reactions were per-
formed in an Applied Biosystems 7500 Detection system
using Maxima SYBR Green/ROX qPCR Master Mix Assays
(Fermentas, USA) following reference [17, 18]. The house-
keeping gene β-Actin was chosen as the loading control.
The expression of targeted genes’ mRNA was determined
from the threshold cycle (Ct), and relative expression levels
were normalized to the expression of human β-Actin
mRNA and calculated by the 22-△△ Ct method. Primers
which used in real-time RT-PCR were listed in Table 1.
Antibodies and immunoblotting analysis (western
blotting)
Antibodies against ERα, ETS-1, MMP1, MMP9, SRC-1,
AIB-1, Lamin A/C, β-Actin and GAPDH were obtained
from Santa Cruz Biotechnology (Santa Cruz Biotech, CA,
USA). Antibodies against NCoR and SMRT were gift from
Dr. Jiajun Cui and descripted in reference [14]. A polyclonal
anti-rabbit IgG antibody and anti-Flag monoclonal antibody
both conjugated with the horseradish peroxidase (HRP)
were from Sigma (St. Louis, MO, USA). SH-SY5Y or
MDA-MB-231 cells were seeded and cultured in six-well
plates (Corning, NY, USA). The cells, which were treated
with indicated concentration compounds or transfected
with vectors, were harvested by RIPA buffer supplemented
with protease inhibitors cocktails (Sigma, Louis, MO). Total
protein samples were performed by SDS-PAGE and trans-
printed to poly-vinylidene fluoride (PVDF) membranes
(Millipore, Billerica, MA). Then, membranes were blocked
with 10 % BSA in TBST buffer and then incubated 2 h at
37°Cwith rabbit primary antibody against human ERα
(1:1,000); rabbit primary antibody against ETS-1 (1:2000);
mouse primary antibody against human MMP1 (1:500),
MMP9 (1:1000), SRC-1 (1:1000), AIB-1 (1:1000); rabbit pri-
mary antibody against human NCoR (1:500) or SMRT
(1:500) and mouse primary monoclonal antibody against
human GAPDH diluted in TBST containing 10 % BSA and
subsequently washed three times in TBST for 5 min each.
Then membranes were incubated with the HRP-conjugated
secondary antibodies (1:5000) after washed three times in
TBST for 5 min each. At last, the blot was developed with
enhanced chemiluminescence reagents (Pierce, USA) by X-
ray films. When incubating HRP-Flag monoclonal antibody
(1:5000), the blots were visualized without incubating sec-
ondary antibody. The blots were performed on three inde-
pendent occasions with similar results.
Immunoprecipitation
SH-SY5Y cells were transfected with FLAG-ERα or
FLAG-ETS-1 using Lipofectamine 2000. Then, cells were
harvested and lysed in the immunoprecipitation buffer
after 18–24 h culture at 4 °C. The Co-IP analyze was
performed with anti-FLAG monoclonal antibody (Sigma-
Aldrich, USA) and then detected by immunoblotting
assays treated without or with 100nM E2 following the
protocols descripted in reference [19, 20].
GST-pull down assay
ERα or ETS-1 was expressed as GST-fusion proteins in
Escherichia coli (E. coli) strain DH5α and bound to the
glutathione-Sepharose beads purified as described by the
manufacturer (Amersham Biosciences). The expression
plasmid for FLAG-ERα or FLAG-ETS1 was used for the
expression in HEK293 cells and purified by FLAG-
beads. FLAG-ERα or FLAG-ETS-1 was incubated with
GST alone, GST-ETS-1 or GST-ERα fusion protein
bound to glutathione-Sepharose beads in 500 μl of bind-
ing buffer at 4 °C for 4 h. The beads were precipitated,
washed three times with binding buffer, and subjected to
SDS-PAGE and WB (western blot) assays.
ChIP
The recruitment of transcriptional factor (ETS-1) or nu-
clear receptor (ERα) to its DNA binding elements was
analyzed by ChIP assays as protocols described previ-
ously [15, 19, 21]. SH-SY5Y cells were transfected with
plasmids or treated with indicated compounds, and fixed
by adding formaldehyde to the medium. After cross-
linking, glycine was added at a final concentration of
125 mM, and the cells were harvested with lysis buffer.
The cell nuclei sub-fractions were pelleted by centrifuga-
tion and resuspended in nuclear lysis buffer. The nuclear
lysates were sonicated to generate DNA fragments of
Table 1 Real-time RT-PCR Primers
Target genes Primers
MMP1 Forward primer: 5′-aagccatcacttaccttgcact-3′
Reverse primer: 5′-tcagagaccttggtgaatgtca-3′
MMP9 Forward primer: 5′-ctggagacctgagaaccaa-3′
Reverse primer: 5′-actgctcaaagcctccacaaga-3′
β-Actin Forward primer: 5′-ctccatcctggcctcgctgt-3′
Reverse primer: 5′-gctgtcaccttcaccgttcc-3′
Table 2 The dose-effect of agents on ETS-1′s transcriptional
activity
Agents IC50/EC50 (nM) ICmax/ECmax (μM) R
2 Value P Value
E2 18.75 ± 1.22 0.10 0.94 0.0024
HGF 6.22 ± 0.75 (ng/ml) 0.03 0.95 0.0098
ICI-182780 26.53 ± 4.15 0.10 0.92 0.015
ARQ-197 17.75 ± 3.66 0.30 0.91 0.0044
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0.5-1 kb, and then ChIP assays were performed with
antibodies against ERα, ETS-1, SRC-1, AIB-1, NCoR or
SMRT. Real-time PCR amplification was performed with
DNA extracted from the ChIP assay and primers flank-
ing the ETS binding elements in promoter region of
mmp1 gene.
The primers used in ChIP analysis were as follows [13]:
mmp1 gene’s promoter forward:’-TTCCAGCCTTTT
CATCATCC-3′; reverse: 5′-CGGCACCTGT ACTGAC
TGAA-3′; Input Genomic DNA forward: 5′-AACCTAT




The localization of ERα and ETS-1 was determined by the
subcellular fractionation assays following the protocol
descripted in reference [22]. Briefly, SH-SY5Y cells were
homogenized using a Dounce homogenizer and the hom-
ogenate was centrifuged at 366 g for 10 min. Next, the
pellets were analyzed as the nuclear fraction. The super-
natant was centrifuged again at 13201 g for 10 min, and
the final supernatant was analyzed as the cytoplasmic frac-
tion. Then, IB analysis was performed. Anti-β-Actin rabbit
antibody (1:5000) was used to detect the cytoplasmic frac-
tion, and anti-Lamin A/C mouse antibody (1:2500) was
used to detect the nucleus fraction.
Cell proliferation assays
Cell proliferation was analyzed by MTT-assay as described
previously [23]. The proliferation of SH-SY5Y cells was
determined using a Cell Titer 96® nonradioactive cell prolif-
eration assay kit (Promega, USA), according to the manu-
facturer’s instructions. Cells, which were transfected with
plasmids or treated with agents, were seeded into 96-well
plate and incubated at 37 °C with 5 % CO2. After incubat-
ing for 1 day, 2 days, 3 days, 4 days and 5 days, cells were
harvested and analyzed. Finally, growth curves for each cell
group were drawn according to the volume of O.D. 490 nm
from the 96-well plate reader. The MTT cell growth assays
were performed for three independent times.
Anchorage-independent growth assay
SH-SY5Y cells were treated with agents. Cells were plated
on six-well plates (500 per well) (Corning, Corning, NY),
with a bottom layer of 0.7 % low-melting-temperature
agar in DMEM and a top layer of 0.25 % agar in DMEM.
Colony number was the mean ± SD of three independent
experiments scored after 3–4 weeks of growth [23].
Trans-well invasion and migration assay
The invasion and migration assays were performed in
24-well plates using the trans-well chamber (Corning,
NY, USA) fitted with a polyethylene terephthalate filter
membrane with 8-μm pores. For invasion assay, the
membrane undersurface was coated with 30 μl ECM
(Extracellular matrix) gel from Engelbreth-Holm-Swarm
mouse sarcoma (BD Biosciences, Bedford, MA, USA)
mixed with RPMI-1640 serum free medium in 1:5 dilu-
tion for 4 h at 37 °C. The top chambers of the trans-
wells were filled with 0.2 ml of cells (5 × 105 cells/ml) in
serum-free medium, and the bottom chambers were
filled with 0.25 ml of RPMI 1640 medium containing
10 % FBS. The cells were incubated in the trans-wells at
37 °C in 5 % CO2 for 4 h or 24 h. The relative invading
cells were measured following the methods descripted in
reference [4]. Values were corrected for protein concen-
tration and are presented as the mean ± SD of three in-
dependent experiments, each with two samples per
experimental treatment [24]. The mean values were ob-
tained from three replicate experiments.
Ethics statement
Our studies are in compliance with the Helsinki Declar-
ation. Our work aims to declare the cross-talk between
transcriptional factors and the underlying molecular
mechanisms. We did not use any materials from clinical
specimens. And the methods did not relate to the clin-
ical trial or methods. Only the cell lines used in this
work were obtained from the typical biological sample
preservation Center but not clinical specimens, human
subjects, human material or data.
Statistical analysis
The WB results were analyzed by the ALPHA INNO-
TECH analysis software. The relative expression level
was calculated: (indicated group protein expression level
/ loading control expression level) / (control group pro-
tein expression level / loading control expression level).
All statistical significance analyses were performed using
SPSS statistical software. P-value of <0.05 was consid-
ered statistical significant. Statistical significance in the
luciferase activity and cell growth assays was analyzed by
Bonferroni correction with or without two ways
ANOVA. The R2, P and EC50/IC50 values were calcu-
lated by Origin 8.5 software.
Results
Estrogen enhances the transcriptional activity of ETS-1
To discover the role estrogen plays in regulating the tran-
scriptional activity of ETS-1, a common endogenous estro-
gen E2 was employed in luciferase assays. SH-SY5Y cells
were co-transfected with ETS-1 binding site EBS-Luc re-
porters. E2 increased the activity of ETS-1 in a dose-
dependent manner (Fig. 1a, Table 2), the EC50 value is 18.75
± 1.22nM. The antagonist of ERα ICI-182780 down-
regulated ETS-1’s activity induced by E2 (Fig. 1b, Table 2),
the IC50 value is 26.53 ± 4.15nM. To confirm the activity of
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ETS-1 in SH-SY5Y cells, the agonist (HGF) and antagonist
(ARQ-197) of ETS-1 signaling pathway were used. As
shown in Fig. 1c and d, HGF increased the EBS-Luc re-
porter activity in a dose dependent manner, the EC50 value
is 6.22 ± 0.75 ng/ml; whereas ARQ-197 inhibited the EBS-
Luc activity induced by HGF, the IC50 value is 17.75 ±
3.66nM. These all indicated that ERα increased the activity
of ETS-1 in a ligand dependent manner.
Next, the potential cross-talk of ERα and ETS-1 was
detected. SH-SY5Y cells were co-transfected with EBS-
Luc, or ETS-1 responsive genes mmp1, mmp9, c-Met
and uPA luciferase reporters and harvested and ana-
lyzed by luciferase assays. As shown in Fig. 1e-i, both E2
and HGF synergistically enhanced the activity of EBS-
Luc, MMP1-Luc and MMP9-Luc. ICI-182780 inhibited
the effect of E2 but not HGF; whereas ARQ-197 almost
blocked HGF’s effect but not E2. Moreover, ICI-182780
did not reduce the effect of HGF on ETS-1 activity. Sug-
gest both estrogen and HGF regulate ETS-1 activity
independently.
Then, the transcription and expression level of
MMP1/9 was tested by RT-PCR and western blot. As
shown in Fig. 2a and b, E2 and HGF synergistically en-
hanced the mRNA level and protein level of MMP1 and
MMP9. ICI-182780 blocked the effect of E2, but not
HGF; whereas ARQ-197 inhibited the effect of HGF but
not E2. Moreover, ICI-182780 did not reduce the activ-
ity of HGF and the antagonist of these two pathways
synergistically reduced the expression of those ETS-1
response genes. These results indicated that ERα activa-
tion may up-regulate the expression of ETS-1 targeted
genes independent of HGF/c-Met signaling, and the
Fig. 1 The effect of estrogen on ETS-1 transcriptional activity. SH-SY5Y cells were co-transfected with EBS (a-e), mmp1 (f), mmp9 (g), c-Met (h) and uPA
(i) reporters; then treated with indicated concentration of E2 (17-β-estradiol, the agonist of ERα), ICI-182780 (the antagonist of ERα), HGF (hepatocyte
growth factor, the agonist of c-Met) or ARQ-197 (the antagonist of c-Met). Cells were harvested and determined by the Luciferase assays. The values
are the mean ± SD from three independent experiments. * P < 0.05
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enhancement of ETS-1 activity induced by E2 would be
mediated by ERα independently.
The specificity of estrogen mediated ETS-1 activity
regulation
To study the specificity of estrogen on regulating ETS-1 ac-
tivity, SH-SY5Y cells, which expresses ERα (Fig. 3a and b),
were stably transfected with empty vector, ERα, control
siRNA, or ERα siRNA for ERα overexpression and knock-
down. Overexpression of ERα enhanced the activity of
EBS-Luc reporter activity only in the presence of E2
(Fig. 3a). Knock-down of endogenous ERα dramatically de-
creased the activity of the EBS-Luc reporters, activated by
E2, in SH-SY5Y cells compared with control (Fig. 3b).
These data indicated that ERα itself is required for the ef-
fect of E2 on ETS-1 activity. Human breast cancer cells
MDA-MB-231, which lacks the ERα but normally expresses
ETS-1, were co-transfected with the EBS-Luc, ERα or
empty vector. As shown in Fig. 3c, in presence of E2, stable
expression of ERα but not empty vector enhanced the tran-
scriptional activity of ETS-1 for 4.3-folds. This result fur-
ther showed that ERα regulates the transcriptional activity
of ETS-1 induced by estrogen.
Next, the involvement of ETS-1 in ERα-mediated tran-
scription needs to be examined. Overexpression of ETS-1
increased the activity of EBS-Luc (Fig. 3d); whereas this
activity activated by E2 decreased dramatically in the
down-regulation of endogenous ETS-1′s (Fig. 3d) protein
level via its siRNA in SH-SY5Y cells. These results indi-
cated estrogen mediated induction of ERα leads to up-
regulation of ETS-1 transcriptional activity, and finally
increases expression of ETS-1 downstream genes, such as
MMP1/9 in an ETS-1 dependent manner.
ERα interacts with ETS-1 in an estrogen-dependent
manner
Following our previous observation that ETS-1 interacts
with ERα, detailed study was performed. SH-SY5Y cells
were transfected with the FLAG-ERα or FLAG empty
plasmid. Then the co-immunoprecipitation (co-IP) and
immunoblotting (IB) assays were performed. The results
showed that FLAG-ERα interacted with the endogenous
ETS-1 (Fig. 4a) in the presence of E2. From converse co-
IP assay, we showed that FLAG-ETS1 interacted with
endogenous ERα (Fig. 4b) in E2-dependent manner. To
determine whether ETS-1 interacts with ERα directly,
the purified GST-ERα or GST-ETS1 was incubated with
purified FLAG-ETS1 or FLAG-ERα for GST pull-down
assays. The results showed that GST-ERα interacts with
FLAG-ETS1 (Fig. 4c) and GST-ETS1 interacts with
FLAG-ERα (Fig. 4d). Taken together, these observations
indicated that ETS-1 binds to ERα directly, suggested
that E2 may regulate ETS-1′s activity via ERα/ETS-1
interaction.
Effect of estrogen on ETS-1′s cytoplasm/nuclear
translocation
Following the protein-interaction results, it is necessary
to investigate the detailed mechanism of ERα-mediated
ETS-1 activity regulation. SH-SY5Y cells were treated
with E2, ICI-182780 or ARQ-197. Then, cells were col-
lected and separated into cytoplasmic/nuclear subcellu-
lar fractions, and ERα or ETS-1 was detected by western
blot. As shown in Fig. 5, ERα and ETS-1 could be de-
tected in both the cytoplasm and nuclear fractions. E2
increased the proportion of ERα and ETS-1 in the
nuclear (Fig. 5). ICI-182780 disrupted the E2 induced
cytoplasm/nuclear translocation of ERα and ETS-1
(Fig. 5). ARQ-197 did not modulate the effect of E2 on
ETS-1′s translocation (Fig. 5). After treating ICI-182780,
a tiny reduction of ERα could be observed than that in
breast cancer cells; it might due to the cell type specifi-
city and not be a common phenomenon due to genetic
background of SH-SY5Y cells different from breast can-
cer cells. Those results are in accord with the former
findings and suggest ERα would regulate ETS-1 activity
Fig. 2 The effect of estrogen and HGF on the expression of ETS-1 targeted genes. SH-SY5Y cells were treated with indicated concentration of E2,
ICI-182780, HGF or ARQ-197. a Identification of ETS-1 responsive genes’ mRNA level by Real-time RT-PCR assays. Cells were treated with indicated
concentration of agents, and then be examined by RT-PCR assays. b The protein level of ETS-1, MMP1/9 and ERα was identified by Western blot.
The values are the mean ± SD from three independent experiments. * P < 0.05
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Fig. 3 (See legend on next page.)
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via altering its cytoplasm/nuclear translocation dependent
to E2 but independent to HGF/c-Met.
Effect of estrogen on the mmp1′s promoter recruitment
of ETS-1
To further investigate regulatory activity of estrogen on
ETS-1, we performed ChIP assays. Binding of ETS-1 at
the mmp1 promoter, which contains the EBS, was de-
tected by ChIP. As expected, NCoR, SMRT, ETS-1, ERα,
SRC-1 and AIB-1 were recruited to the mmp1 promoter
(Fig. 6a and b). In addition, E2 potentiated the recruit-
ment of ERα, ETS-1, SRC-1 or AIB-1 to mmp1 pro-
moter; whereas ICI-182780 down-regulated this effect
(Fig. 6a). Meanwhile, E2 also reduced the recruitment of
NCoR and SMRT to the promoter (Fig. 6B), which are
negative transcriptional regulators of nuclear receptors.
We next studied whether these transcriptional regula-
tors participate in this estrogen-ETS-1 axis. SH-SY5Y cells
were co-transfected with SRC-1, AIB-1, NCoR or SMRT
plasmids, and then treated without or with E2. As shown
in Fig. 6C and D, activity of ETS-1 induced by E2 was en-
hanced by transfection of SRC-1 or AIB-1 vectors, and re-
duced after transfection of NCoR or SMRT vectors. These
results suggested that estrogen would enhance the recruit-
ment of ETS-1 and transcription factor co-regulators to
the downstream gene’s promoter region.
ERα Increases proliferation of SH-SY5Y Cells
To study whether ERα activation enhances SH-SY5Y
cells proliferation, we performed MTT, trans-well, and
soft agar assays. For MTT-assays, SH-SY5Y cells were
cultured in phenol red-free DMEM added 2 % charcoal-
stripped FBS (Fig. 7a and b) or in normal DMEM added
10 % normal FBS (Fig. 7c and d). As shown in Fig. 7, up-
regulation of ERα activity markedly enhanced the prolif-
eration ability of SH-SY5Y cells, while down-regulation
of ERα activity induced by E2 markedly reduced SH-
SY5Y cells growth. Treatment of E2 promoted the prolif-
eration of SH-SY5Y cells and ICI-182780 down regulated
the growth of SH-SY5Y cells.
Next, the role of ERα on SH-SY5Y cell’s anchor-
independent growth was examined. ERα’s activation mark-
edly enhanced SH-SY5Y cell growth (Fig. 7e and f). Im-
pairment of ERα activation reduced cell proliferation
(Fig. 7e and f). These data showed that estrogen partici-
pates in cell anchor-independent growth or invasion.
Fig. 4 ERα can interact with ETS-1. a-b Interaction of endogenous ERα, or ETS-1 with exogenous FLAG-ETS-1, or FLAG-ERα. FLAG-tagged ERα (a)
or FLAG-tagged ETS-1 (b) or FLAG empty vector (a-b) was transfected into SH-SY5Y cells. Cell lysates were immunoprecipitated by anti-FLAG
monoclonal antibody, and the precipitates were then immunoblotted with anti-ETS-1 or anti-ERα antibody. c-d In vitro interaction of ETS-1 with
ERα. Glutathione-Sepharose beads bound with GST-ERα (c), GST-ETS-1 (d) or with GST (c-d) were incubated with purified FLAG-labeled ETS-1 or
ERα in the presence or absence of 100nM E2. After washing the beads, the bound proteins were eluted and subjected to SDS-PAGE and IB assays
(See figure on previous page.)
Fig. 3 ERα but not the HGF/c-Met mediated the enhancement of ETS-1 activity induced by estrogen. a,b Cells were treated with 100nM E2 (the
ECmax concentration of estrogen). The SH-SY5Y cells were stably transfected with empty vector (a), ERα vectors (a), control siRNA (b,d), ERα siRNA (b),
ETS-1 vector (d) or ETS-1 siRNA (d); whereas MDA-MB-231 cells were stably transfected with empty vector (c) or ERα vectors (c). Then, cells which were
co-transfected with EBS-Luc reporters and harvested for the Luciferase analysis. The expression of ERα and ETS-1 were determined by immunoblots,
and the results were showed at the panels at the bottom of the figure. The values are the mean ± SD from three independent experiments. * P < 0.05
Cao et al. BMC Cancer  (2015) 15:491 Page 8 of 14
Fig. 5 Effect of E2 on ETS-1 cytoplasm/nucleus translocation. SH-SY5Y cells were treated with indicated amount of E2, ICI-182780, or ARQ-197.
Then, cells were fractionated into the cytoplasmic fractions and nucleus fractions. The fractions were detected with ETS-1 and ERα antibodies.
The Lamin A/C was used as the nucleus indicator. The ß-actin was used as the cytoplasmic marker
Fig. 6 Estradiol modulated the recruitment of ETS-1 and transcriptional co-regulator to mmp1 promoter region. a The recruitment of ETS-1, ERα,
SRC-1 and AIB-1 to the mmp1 promoter was detected by ChIP assay. b The recruitment of ETS-1, ERα, NCoR and SMRT to the mmp1 promoter
was detected by ChIP assay. (c-d) SH-SY5Y cells were stimulated with 10nM E2 for 1 h. SH-SY5Y cells were transfected with SRC-1 (a), AIB-1 (a),
NCoR-1 (b), or SMRT (b) expression vectors or empty vectors. Cells were then harvested for the luciferase assay. The values are the mean ± SD
from three independent experiments. Western blot (bottom) indicates the expression level of proteins with anti-SRC1, anti-AIB1, anti-NCoR, or
anti-SMRT antibodies. GAPDH was used as loading control. *P < 0.05
Cao et al. BMC Cancer  (2015) 15:491 Page 9 of 14
Fig. 7 Effect of estrogen and ERα on SH-SY5Y cells proliferation and anchor-independent growth. SH-SY5Y cells, which were cultured in phenol
red-free DMEM added 2 % charcoal-stripped FBS (a and b) or in normal DMEM added 10 % normal FBS (c and d), were treated with E2 (100nM) or
ICI-182780 (300nM). Cells were then measured by MTT assay (a-d) or soft agar assay (e). Colony was shown in the photographs (e). (a-d, f) Data are
mean ± SD of triplicate independent experiments and have been repeated 3 times with similar numbers. The effect of Estrogen on ETS-1 targeted
genes MMP1 or MMP9 was detected by Western blot (g). *P < 0.05 versus Solvent control (DMSO) or E2; *P < 0.05 versus Solvent control (DMSO) or
ICI-182780; *P < 0.05 versus with E2 or ICI-182780
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Moreover, the effect of ERα activity on SH-SY5Y cell’s
invasion and migration was examined. Up-regulation of
ERα’s activity markedly enhanced SH-SY5Y cell invasion
and migration (Fig. 8a,b,d). Our data showed that estro-
gen increased the expression of ETS-1 targeted genes
MMP1/9, which participated in cell migration or inva-
sion (Fig. 8c). Taken together, ERα activation promoted
the SH-SY5Y cell’s proliferation, anchor-independent
growth, invasion and migration in a ligand-dependent
manner.
Discussion
In this study, we identified the nuclear receptor/transcrip-
tion factor ERα as an ETS-1 interacting protein and regu-
lator. The protein-interaction between ERα and ETS-1
has been validated by in vitro and in vivo assays, including
co-immunoprecipitation or GST pull-down. ERα activated
by its agonist increased the transcriptional activity of ETS-
1 and the expression of ETS-1 responsive genes MMP1/9.
In contrast, impairment of ERα activation via its antagon-
ist reduced ETS-1′s activity. Moreover, the effect of ERα
on ETS-1 was further examined in MDA-MB-231 and
SH-SY5Y cells, revealed that ERα mediates the induction
of ETS-1 induced by estrogen E2. Moreover, exogenous
E2 stimulated neuroblastoma cell proliferation, migration
and invasion. We also showed a positive regulatory feed-
back in E2/ETS-1 signaling that E2 mediated activation of
ERα increase ETS-1 activity and ETS-1 protein level. We
hypothesis that E2 mediated increasing of ETS-1 level is
one of the downstream effects that ensure the accessibility
of the signaling.
ETS-1 is a transcription factor, which has been impli-
cated as a downstream effector of HGF/c-Met signaling
pathway [25]. In nucleus, ETS-1 mediates transcription
via binding to the ETS binding sequence (EBS) in pro-
moter/enhancer regions of targeting gene [25]. HGF
would induce expression of ETS-1 target genes include
the ETS-1, MMPs, urokinase-type plasminogen activator,
growth factors and the growth factor receptor like c-Met
or HER2 [25–27]. Accumulating evidences have shown
that ETS-1 could interact with several co-regulators, in-
cluding co-activators or co-repressors. The transcriptional
activity of ETS-1 was modulated by these co-regulators.
Sequence-motif LxxLL in Loop 1 of ETS domain has been
identified to the recognition site for co-regulators binding,
such as SRC/p160 [28, 29]. The p160 family of steroid co-
regulator was thought to be exclusively associated with
nuclear receptors and some steroid-independent tran-
scription factors, including NK-kB, AP1, P53, ER81, ETS-
1 and ETS-2 [20]. Since ERα is a ligand-dependent nuclear
receptor, ERα mediated stimulation of cancerous cells
proliferation requires estrogen, such as E2 [30–34]. We
showed that ERα could efficiently enhance ETS-1 tran-
scriptional in the SH-SY5Y cells were cultured in phenol
red-free medium with charcoal dextran-treated fetal bo-
vine serum only supplemented estrogen. Therefore, ERα
itself was required for the activity of ETS-1′s transcrip-
tional activity induced by E2. Moreover, ERα would be
trans-located into nucleus in respond to estrogen [33] and
binds to the genome DNA of the estrogen responsive
element (ERE) sequences to regulate the expression of
downstream genes [34]. Combine with our observations
that estrogen induced the accumulation of ETS-1 in nu-
clear and the recruitment of ETS-1 to its targeted genes’
promoter, it is likely that activated ERα may interact with
ETS-1 and induce its translocation into nuclear and re-
cruit each other onto their DNA binding sites. Further
time-effect or dose-effect experiments should be done to
further discover the mechanism of estrogen/ERα on ETS-
1 cytoplasm/nuclear translocation.
The ETS family includes a large number of transcrip-
tional regulatory proteins. All ETS family members share
an 85 amino acid conserved DNA binding domains (ETS
domain) in the C-terminal of the protein [35]. They may
play compensatory roles in physiological, pharmaceutical
and pathological regulation of growth, migration, invasion,
apoptosis and oncogenic transformation [36] process.
Thus, we cannot exclude the possibility that ERα also in-
teracts with other ETS family members, such as ETS-2. It
is valuable to examine the cross-talk of ERα with other
members of ETS1 family besides ETS-1.
Although ERα was detected in endocrine-related can-
cers, besides to breast cancer, the function of ERα need to
be further discovered. ERα inhibitor or antagonist, ICI-
182780 or tamoxifen would inhibit the growth of breast
cancer, HCC, neuroblastoma, and glioma cells [37]. It’s
well known that ERα associates with some other signaling
pathways [5, 6, 38]. Jiang et al., 2013 showed that protein
MEMO mediated the interaction of HER2 and ERα [38].
Egloff et al., 2009 reported that estrogen increased tran-
scription from ERE and induced activation of MAPK in
HNSCC cell lines [4]. In spite of those accumulating dis-
coveries, whether ERα plays a role in neuroblastoma
oncogenesis is still unknown. Our work extended the un-
derstanding of ERα function and it is necessarily to further
learn the roles of cross-talk of ERα with relative signaling
pathways in neuroblastoma cells.
The proliferation, invasion and migration are the main
features of the metastatic malignancies, which are markers
in cancer progression and are major causes of mortality.
Recent data showed that several important genes partici-
pated in the regulation of cancer cells’ proliferation. To
date, a subset of patients would suffer from the tumor
with ERα positively expressing, such as HCC, neuroblast-
oma and ovarian cancer. In this work, based on the previ-
ous data, we choose SH-SY5Y as a neuroblastoma cell
model. Estrogen treatment enhanced the proliferation,
anchor-independent growth, invasion and migration of
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ERα-positive neuroblastoma cell SH-SY5Y and up-
regulated the transcriptional activity of ETS-1. Thus, we
deduced that estrogen level would be a novel bio-marker
or risk factor in the prognosis of neuroblastoma, and the
anti-endocrine therapies targeted to ERα would be a novel
strategy of neuroblastoma treatment.
Conclusions
In summary, estrogen/ERα is involved in neuroblastoma
proliferation and enhanced the activation of ETS-1. This
notion is supported by the fact that E2 treatment
enhanced the transcription factor activity of ETS-1
through promoting ERα/ETS-1 interaction. Here, we
demonstrate that the interaction of ERα and ETS-1 partic-
ipates in regulation of neuroblastoma cell’s proliferation,
migration and invasion in the presence of estrogen. These
findings would help us to understand more about E2/ERα
signaling in cancerous cell proliferation and also provide a
new potential therapeutic target of human neuroblastoma.
Abbreviations
ERα: Estrogen receptor α; HCC: Hepatocellular Carcinoma; HNSCC: Head and
neck squamous cell carcinoma; ETS-1: E26 transformation specific sequence
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